Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03562871
Recruitment Status : Active, not recruiting
First Posted : June 20, 2018
Last Update Posted : May 19, 2021
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
IO Biotech

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : February 6, 2021
Estimated Study Completion Date : February 2022
Publications: